Abstract
Previous studies have indicated the important roles of MYCN in tumorigenesis and progression of neuroblastoma (NB), the most common extracranial solid tumor derived from neural crest in childhood. However, the regulatory mechanisms of MYCN expression in NB still remain largely unknown. In this study, through mining public microarray databases and analyzing the cis-regulatory elements and chromatin immunoprecipitation data sets, we identified CCCTC-binding factor (CTCF) as a crucial transcription factor facilitating the MYCN expression in NB. RNA immunoprecipitation, RNA electrophoretic mobility shift assay, RNA pull down and in vitro binding assay indicated the physical interaction between CTCF and MYCN opposite strand (MYCNOS), a natural noncoding RNA surrounding the MYNC promoter. Gain- and loss-of-function studies revealed that MYCNOS facilitated the recruitment of CTCF to its binding sites within the MYCN promoter to induce chromatin remodeling, resulting in enhanced MYCN levels and altered downstream gene expression, in cultured NB cell lines. CTCF cooperated with MYCNOS to suppress the differentiation and promote the growth, invasion and metastasis of NB cells in vitro and in vivo. In clinical NB tissues and cell lines, CTCF and MYCNOS were upregulated and positively correlated with MYCN expression. CTCF was an independent prognostic factor for unfavorable outcome of NB, and patients with high MYCNOS expression had lower survival probability. Taken together, these results demonstrate that CTCF cooperates with noncoding RNA MYCNOS to exhibit oncogenic activity that affects the aggressiveness and progression of NB through transcriptional upregulation of MYCN.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Westermann F, Schwab M . Genetic parameters of neuroblastomas. Cancer Lett 2002; 184: 127–147.
Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983; 305: 245–248.
Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM . Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16: 2985–2995.
Lutz W, Stöhr M, Schürmann J, Wenzel A, Löhr A, Schwab M . Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996; 13: 803–812.
Tanaka N, Fukuzawa M . MYCN downregulates integrin alpha1 to promote invasion of human neuroblastoma cells. Int J Oncol 2008; 33: 815–821.
Tee AE, Ling D, Nelson C, Atmadibrata B, Dinger ME, Xu N et al. The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1. Oncotarget 2014; 5: 1793–1804.
Thomas WD, Raif A, Hansford L, Marshall G . N-myc transcription molecule and oncoprotein. Int J Biochem Cell Biol 2004; 36: 771–775.
Inge TH, Casson LK, Priebe W, Trent JO, Georgeson KE, Miller DM et al. Importance of Sp1 consensus motifs in the MYCN promoter. Surgery 2002; 132: 232–238.
Nutt SL, Morrison AM, Dörfler P, Rolink A, Busslinger M . Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J 1998; 17: 2319–2333.
Zhang X, Xing G, Saunders GF . Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1. Anticancer Res 1999; 19: 1641–1648.
Kramps C, Strieder V, Sapetschnig A, Suske G, Lutz W . E2F and Sp1/Sp3 synergize but are not sufficient to activate the MYCN gene in neuroblastomas. J Biol Chem 2004; 279: 5110–5117.
Suenaga Y, Kaneko Y, Matsumoto D, Hossain MS, Ozaki T, Nakagawara A . Positive auto-regulation of MYCN in human neuroblastoma. Biochem Biophys Res Commun 2009; 390: 21–26.
Yu M, Ohira M, Li Y, Niizuma H, Oo ML, Zhu Y et al. High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma. Int J Oncol 2009; 34: 931–938.
Pandey GK, Mitra S, Subhash S, Hertwig F, Kanduri M, Mishra K et al. The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. Cancer Cell 2014; 26: 722–737.
Vance KW, Sansom SN, Lee S, Chalei V, Kong L, Cooper SE et al. The long non-coding RNA Paupar regulates the expression of both local and distal genes. EMBO J 2014; 33: 296–311.
Liu PY, Erriquez D, Marshall GM, Tee AE, Polly P, Wong M et al. Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression. J Natl Cancer Inst 2014, e-pub ahead of print 6 June 2014 doi:10.1093/jnci/dju113.
Armstrong B, Krystal G . Isolation and characterization of complementary DNA for N-cym, a gene encoded by the DNA strand opposite to N-myc. Cell Growth Differ 1992; 3: 385–390.
Jacobs J, van Bokhoven H, van Leeuwen F, Hulsbergen-van de Kaa CA, de Vries I, Adema G et al. Regulation of MYCN expression in human neuroblastoma cells. BMC Cancer 2009; 9: 239.
Suenaga Y, Islam SMR, Alagu J, Kaneko Y, Kato M, Tanaka Y et al. NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas. PLoS Genet 2014; 10: e1003996.
Yang JH, Li JH, Jiang S, Zhou H, Qu LH . ChIPBase: a database for decoding the transcriptional regulation of long non-coding RNA and microRNA genes from ChIP-Seq data. Nucleic Acids Res 2013; 41: D177–D187.
Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005; 21: 2933–2942.
Hasan MK, Nafady A, Takatori A, Kishida S, Ohira M, Suenaga Y et al. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma. Sci Rep 2013; 3: 3450.
Henriksen J, Haug B, Buechner J, Tomte E, Lokke C, Flaegstad T et al. Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma. BMC Dev Biol 2011; 11: 1.
Michel AM, Fox G, M Kiran A, De Bo C, O'Connor PB, Heaphy SM et al. GWIPS-viz: development of a ribo-seq genome browser. Nucleic Acids Res 2014; 42: D859–D864.
Wang X, Arai S, Song X, Reichart D, Du K, Pascual G et al. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature 2008; 454: 126–130.
Sun S, Del Rosario Brian C, Szanto A, Ogawa Y, Jeon Y, Lee Jeannie T . Jpx RNA activates Xist by evicting CTCF. Cell 2013; 153: 1537–1551.
Saldaña-Meyer R, González-Buendía E, Guerrero G, Narendra V, Bonasio R, Recillas-Targa F et al. CTCF regulates the human p53 gene through direct interaction with its natural antisense transcript, Wrap53. Genes Dev 2014; 28: 723–734.
Lovén J, Zinin N, Wahlström T, Müller I, Brodin P, Fredlund E et al. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc Natl Acad Sci USA 2010; 107: 1553–1558.
Zhang H, Qi M, Li S, Qi T, Mei H, Huang K et al. microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol Cancer Ther 2012; 11: 1454–1466.
Zhang H, Pu J, Qi T, Qi M, Yang C, Li S et al. MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha. Oncogene 2014; 33: 387–397.
Li D, Mei H, Qi M, Yang D, Zhao X, Xiang X et al. FOXD3 is a novel tumor suppressor that affects growth, invasion, metastasis and angiogenesis of neuroblastoma. Oncotarget 2013; 4: 2021–2044.
Pession A, Tonelli R . The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. Curr Cancer Drug Targets 2005; 5: 273–283.
Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA . MYCN oncoprotein targets and their therapeutic potential. Cancer Lett 2010; 293: 144–157.
Lin CY, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012; 151: 56–67.
Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN- driven cancer. Cell 2014; 159: 1126–1139.
Filippova GN, Fagerlie S, Klenova EM, Myers C, Dehner Y, Goodwin G et al. An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol 1996; 16: 2802–2813.
Phillips JE, Corces VG . CTCF: master weaver of the genome. Cell 2009; 137: 1194–1211.
Rao SS, Huntley MH, Durand NC, Stamenova EK, Bochkov ID, Robinson JT et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell 2014; 159: 1665–1680.
De La Rosa-Velázquez IA, Rincón-Arano H, Benítez-Bribiesca L, Recillas-Targa F . Epigenetic regulation of the human retinoblastoma tumor suppressor gene promoter by CTCF. Cancer Res 2007; 67: 2577–2585.
Witcher M, Emerson BM . Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol Cell 2009; 34: 271–284.
Soto-Reyes E, Recillas-Targa F . Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines. Oncogene 2010; 29: 2217–2227.
Docquier F, Farrar D, D'Arcy V, Chernukhin I, Robinson AF, Loukinov D et al. Heightened expression of CTCF in breast cancer cells is associated with resistance to apoptosis. Cancer Res 2005; 65: 5112–5122.
Huang K, Jia J, Wu C, Yao M, Li M, Jin J et al. Ribosomal RNA gene transcription mediated by the master genome regulator protein CCCTC-binding factor (CTCF) is negatively regulated by the condensin complex. J Biol Chem 2013; 288: 26067–26077.
Chernukhin IV, Shamsuddin S, Robinson AF, Carne AF, Paul A, El-Kady AI et al. Physical and functional interaction between two pluripotent proteins, the Y-box DNA/RNA-binding factor, YB-1, and the multivalent zinc finger factor, CTCF. J Biol Chem 2000; 275: 29915–29921.
Shoji W, Suenaga Y, Kaneko Y, Islam SM, Alagu J, Yokoi S et al. NCYM promotes calpain-mediated Myc-nick production in human MYCN-amplified neuroblastoma cells. Biochem Biophys Res Commun 2015; 461: 501–506.
Kaneko Y, Suenaga Y, Islam SM, Matsumoto D, Nakamura Y, Ohira M et al. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas. Cancer Sci 2015; 106: 840–847.
Jiang G, Zheng L, Pu J, Mei H, Zhao J, Huang K et al. Small RNAs targeting transcription start site induce heparanase silencing through interference with transcription initiation in human cancer cells. PLoS One 2012; 7: e31379.
Li D, Mei H, Pu J, Xiang X, Zhao X, Qu H et al. Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2. Mol Cancer 2015; 14: 47.
Xiang X, Zhao X, Qu H, Li D, Yang D, Pu J et al. Hepatocyte nuclear factor 4 alpha promotes the invasion, metastasis and angiogenesis of neuroblastoma cells via targeting matrix metalloproteinase 14. Cancer Lett 2015; 359: 187–197.
Qu H, Zheng L, Pu J, Mei H, Xiang X, Zhao X et al. miRNA-558 promotes tumorigenesis and aggressiveness of neuroblastoma cells through activating the transcription of heparanase. Human Mol Genet 2015; 24: 2539–2551.
Sivak LE, Tai KF, Smith RS, Dillon PA, Brodeur GM, Carroll WL . Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines. Oncogene 1997; 15: 1937–1946.
Zheng L, Qi T, Yang D, Qi M, Li D, Xiang X et al. microRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting cyclin D1 and Ets1. PLoS One 2013; 8: e55719.
Zheng L, Pu J, Qi T, Qi M, Li D, Xiang X et al. miRNA-145 targets v-ets erythroblastosis virus E26 oncogene homolog 1 to suppress the invasion, metastasis, and angiogenesis of gastric cancer cells. Mol Cancer Res 2013; 11: 182–193.
Xiang JF, Yin QF, Chen T, Zhang Y, Zhang XO, Wu Z et al. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res 2014; 24: 513–531.
Zheng L, Li D, Xiang X, Tong L, Qi M, Pu J et al. Methyl jasmonate abolishes the migration, invasion and angiogenesis of gastric cancer cells through down-regulation of matrix metalloproteinase 14. BMC Cancer 2013; 13: 74.
Zheng L, Jiang G, Mei H, Pu J, Dong J, Hou X et al. Small RNA interference-mediated gene silencing of heparanase abolishes the invasion, metastasis and angiogenesis of gastric cancer cells. BMC Cancer 2010; 10: 33.
Acknowledgements
We are grateful to Drs William L Carroll and Danny Reinberg for providing vectors. This work was supported by the National Natural Science Foundation of China (81272779, 81372667, 81372401, 81472363, 81402301, 81402408, 81572423), Fundamental Research Funds for the Central Universities (2012QN224, 2013ZHYX003, 01-18-530112, 01-18-530115) and Natural Science Foundation of Hubei Province (2014CFA012).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Zhao, X., Li, D., Pu, J. et al. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression. Oncogene 35, 3565–3576 (2016). https://doi.org/10.1038/onc.2015.422
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2015.422
This article is cited by
-
SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma
Journal of Experimental & Clinical Cancer Research (2022)
-
HNF4A-AS1-encoded small peptide promotes self-renewal and aggressiveness of neuroblastoma stem cells via eEF1A1-repressed SMAD4 transactivation
Oncogene (2022)
-
MiR-103a-3p promotes tumour glycolysis in colorectal cancer via hippo/YAP1/HIF1A axis
Journal of Experimental & Clinical Cancer Research (2020)
-
The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression
Journal of Experimental & Clinical Cancer Research (2020)
-
Association of lncRNA SH3PXD2A-AS1 with preeclampsia and its function in invasion and migration of placental trophoblast cells
Cell Death & Disease (2020)